Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR029 in Pediatric/Young Adult r/r B-ALL
NCT05727683Phase 1Unknown
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relmacabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai Ming Ju Biotechnology. Primary endpoints: Percentage of Participants Experiencing Dose Limiting Toxicities at 28 days and Occurrence of adverse events at 2 years. Status: unknown.
02
Drugs
relmacabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05727683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727683.